

Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication

Practice Guideline From the AAN, AES, and SMFM

Alison M. Pack, MD, MPH, Maryam Oskoui, MD, MSc, Shawniqa Williams Roberson, MEng, MD, Diane K. Donley, MD, Jacqueline French, MD, Elizabeth E. Gerard, MD, David Gloss, MD, MPH&TM, Wendy R. Miller, PhD, RN, CCRN, Heidi M. Munger Clary, MD, MPH, Sarah S. Osmundson, MD, MS, Brandy McFadden, Kaitlyn Parratt, MBBS (Hons 1), Page B. Pennell, MD, George Saade, MD, Don B. Smith, MD, Kelly Sullivan, PhD, Sanjeev V. Thomas, MD, DM, Torbjörn Tomson, MD, Mary Dolan O'Brien, MLIS, PMP, Kylie Botchway-Doe, Heather M. Silsbee, MWC, and Mark R. Keezer, MDCM, PhD

Correspondence

American Academy of Neurology
guidelines@aan.com

Neurology® 2024;102:e209279. doi:10.1212/WNL.0000000000209279

Abstract

This practice guideline provides updated evidence-based conclusions and recommendations regarding the effects of antiseizure medications (ASMs) and folic acid supplementation on the prevalence of major congenital malformations (MCMs), adverse perinatal outcomes, and neurodevelopmental outcomes in children born to people with epilepsy of childbearing potential (PWECP). A multidisciplinary panel conducted a systematic review and developed practice recommendations following the process outlined in the 2017 edition of the American Academy of Neurology Clinical Practice Guideline Process Manual. The systematic review includes studies through August 2022. Recommendations are supported by structured rationales that integrate evidence from the systematic review, related evidence, principles of care, and inferences from evidence. The following are some of the major recommendations. When treating PWECP, clinicians should recommend ASMs and doses that optimize both seizure control and fetal outcomes should pregnancy occur, at the earliest possible opportunity preconceptionally. Clinicians must minimize the occurrence of convulsive seizures in PWECP during pregnancy to minimize potential risks to the birth parent and to the fetus. Once a PWECP is already pregnant, clinicians should exercise caution in attempting to remove or replace an ASM that is effective in controlling generalized tonic-clonic or focal-to-bilateral tonic-clonic seizures. Clinicians must consider using lamotrigine, levetiracetam, or oxcarbazepine in PWECP when appropriate based on the patient's epilepsy syndrome, likelihood of achieving seizure control, and comorbidities, to minimize the risk of MCMs. Clinicians must avoid the use of valproic acid in PWECP to minimize the risk of MCMs or neural tube defects (NTDs), if clinically feasible. Clinicians should avoid the use of valproic acid or topiramate in PWECP to minimize the risk of offspring being born small for gestational age, if clinically feasible. To reduce the risk of poor neurodevelopmental outcomes, including autism spectrum disorder and lower IQ, in children born to PWECP, clinicians must avoid the use of valproic acid in PWECP, if clinically feasible. Clinicians should prescribe at least 0.4 mg of folic acid supplementation daily preconceptionally and during pregnancy to any PWECP treated with an ASM to decrease the risk of NTDs and possibly improve neurodevelopmental outcomes in the offspring.



From the Department of Neurology (A.M.P.), Columbia University, New York City; Departments of Pediatrics and Neurology & Neurosurgery (M.O.), McGill University, Montreal, Quebec, Canada; Departments of Neurology (S.W.R.), Biomedical Engineering (S.W.R.), and Obstetrics and Gynecology (S.S.O.), Vanderbilt University Medical Center, Nashville, TN; Northern Michigan Neurology and Munson Medical Center (D.K.D.), Traverse City, MI; Department of Neurology (J.F.), NYU Grossman School of Medicine, New York City; Feinberg School of Medicine (E.E.G.), Northwestern University, Chicago, IL; The NeuroMedical Center (D.G.), Baton Rouge, LA; Epilepsy Foundation (W.R.M.), Bowie, MD; Department of Neurology (H.M.M.C.), Wake Forest University School of Medicine, Winston-Salem, NC; My Epilepsy Story (B.M.), Nashville, TN; Institute of Clinical Neurosciences (K.P.), Royal Prince Alfred Hospital, Sydney, Australia; Department of Neurology (P.B.P.), University of Pittsburgh School of Medicine, PA; Department of Ob-Gyn (G.S.), Eastern Virginia Medical School, Norfolk; Department of Neurology (D.B.S.), University of Colorado School of Medicine, Aurora; Department of Biostatistics, Epidemiology, and Environmental Health Sciences (K.S.), Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro; Department of Neurology (S.V.T.), Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India; Department of Clinical Neuroscience (T.T.), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden; American Academy of Neurology (M.D.O.B., K.B.-D., H.M.S.), Minneapolis, MN; and Centre Hospitalier de l'Université de Montréal Research Centre (CRCHUM) (M.R.K.), Quebec, Canada.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Approved by the AAN Guidelines Subcommittee on April 24, 2023; by the AAN Quality Committee on June 26, 2023; by the American Epilepsy Society Guidelines and Assessment Committee on July 30, 2023; by the Society for Maternal-Fetal Medicine Publications Committee on September 11, 2023; by the AAN Institute Board of Directors on February 9, 2024; by the Society for Maternal-Fetal Medicine Executive Committee on February 28, 2024, and by the American Epilepsy Society Board of Directors on March 1, 2024.

This article is co-published in *Neurology*, in *Epilepsy Currents*, and on [SMFM.org](https://www.smfm.org). *Neurology* was responsible for peer review of this article.

Glossary

AAN = American Academy of Neurology; aHR = adjusted hazard ratio; ASD = autism spectrum disorder; ASM = antiseizure medication; COI = conflict of interest; MCM = major congenital malformation; NTD = neural tube defect; PD = prevalence difference; PR = prevalence ratio; PWECP = people with epilepsy of childbearing potential; RMD = raw mean difference; SGA = small for gestational age.

Epilepsy is one of the most common neurologic disorders, affecting more than 50 million people worldwide. One in 5 of those affected are people of childbearing potential, based on extrapolations from the proportion of the 2022 US female population aged 15–45 years.¹ Infants born to people with epilepsy are at increased risk of major congenital malformations (MCMs), adverse perinatal outcomes, and adverse neurodevelopmental outcomes.² Multiple factors are associated with this risk, including genetic differences, environmental factors, seizure control, and intrauterine exposure to antiseizure medications (ASMs). The role of folic acid supplementation in mitigating these risks is unclear. Optimizing the treatment of epilepsy is necessary to achieve the most favorable outcomes for persons with epilepsy and their offspring.

In 2009, the American Academy of Neurology (AAN) published the guideline “Practice Parameter update: Management issues for women with epilepsy—Focus on pregnancy: Teratogenesis and perinatal outcomes.”³ The authors concluded that treatment with valproic acid carries a higher risk of MCMs in the offspring of women with epilepsy than treatment with carbamazepine, phenytoin, and phenobarbital, especially if taken in polytherapy. The risk associated with other commonly used ASMs, such as levetiracetam or topiramate, was not evaluated because of limited available evidence. The authors concluded that treatment with valproic acid carried the highest risk of adverse cognitive outcomes in the offspring of women with epilepsy as compared with carbamazepine, although the risk of autism spectrum disorder (ASD) was not addressed because this association was not yet reported in the literature. Infants exposed to any ASM in utero had a higher risk of being born small for gestational age (SGA), but there was no evidence of an increased risk of fetal death.

A separate 2009 practice guideline recommended that preconception folic acid supplementation “may be considered to reduce the risk of MCMs,” but did not provide further guidance on supplementation dosage.⁴ Since 2009, new studies have been published related to the risk of MCMs associated with several ASMs, the association between different ASMs and adverse perinatal or neurodevelopmental outcomes, and the effect of folic acid supplementation.

While the 2009 guidelines described the affected population as “women with epilepsy,” this phrasing does not recognize the important difference between biological sex and socio-cultural gender. In this update, we refer to the affected population with the gender-neutral language, “people with epilepsy of childbearing potential” (PWECP).


In this practice guideline update, we aim to provide guidance to clinicians when choosing an ASM, in monotherapy or polytherapy, in this patient population. We also aim to clarify the potential role of folic acid supplementation among PWECP. This guideline specifically addresses the following 4 clinical questions:

1. What is the prevalence of MCMs associated with intrauterine exposure to specific ASMs, and how does this vary between ASMs in monotherapy vs polytherapy, and at high doses vs low-medium doses of ASMs, in children born to PWECP?
2. What is the prevalence of adverse perinatal outcomes associated with intrauterine exposure to specific ASMs, and how does this vary between ASMs in monotherapy vs polytherapy, and at high doses vs low-medium doses of ASMs, in children born to PWECP?
3. What is the prevalence of adverse neurodevelopmental outcomes associated with intrauterine exposure to specific ASMs, and how does this vary between ASMs in monotherapy vs polytherapy, and at high vs low-medium doses of ASMs, in children born to PWECP?
4. What is the effect of intrauterine exposure to folic acid on the prevalence of MCMs, adverse perinatal outcomes, and neurodevelopmental outcomes, and how does this vary by folic acid dose in children born to PWECP treated with ASMs?

Description of the Analytic Process

The development of this practice guideline followed the 2017 edition of the AAN’s guideline development process manual.⁵ In March 2018, a multidisciplinary panel was recruited to develop the protocol for this guideline. The authors include content experts, methodologists, Guidelines Subcommittee members, an AAN epilepsy quality measure workgroup representative, physician representatives for the American Epilepsy Society and the Society for Maternal-Fetal Medicine, and patient advocates. In accordance with AAN policy, the current lead developer (A.M.P.), and the majority of the panel, has no conflicts of interest (COIs). Five of the 19 guideline developers (J.F., E.G., K.P., G.S., and T.T.) were determined to have COIs, but each COI was judged to be not significant enough to preclude authorship. These 5 developers were not permitted to review or rate the evidence; they served in an advisory capacity to help with the validation of the key

Figure Study Selection



questions, the scope of the literature search, and the identification of seminal articles. They also participated in the recommendation development process. The full author panel was solely responsible for final decisions about the design, analysis, and reporting of this guideline.

This article is a summary of the key findings of the guideline. The complete guideline, including the literature search strategy, details about evidence classification, and the full systematic review of the evidence, is available in eAppendix 1.

Systematic Review of the Evidence

The panel searched Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, Ovid Embase, CINAHL, the Database of Abstracts of Reviews of Effects, ClinicalTrials.gov, and the US Food and Drug Administration literature databases from June 1, 2007, to February 15, 2019, for relevant peer-reviewed articles that met inclusion criteria. The initial search after duplicates were removed yielded 4,039 articles. Using a systematic process detailed in the AAN's guideline development process manual,⁵ 2 review panel members (not the same pair for all articles) independently reviewed the article titles and abstracts for relevance and then reviewed the full text of the articles determined to be relevant

(Figure). Disagreements about inclusion were resolved through discussion between the 2 panelists, with a third reviewer included to break ties when necessary. One hundred eighty-three articles were selected and rated for risk of bias by 2 panel members using the AAN criteria for the classification of causation studies. Class I studies have the lowest risk of bias, and Class IV studies have the highest risk of bias. As per predefined exclusion criteria that are laid out in the process manual,⁵ the panel excluded articles that were assessed as Class IV (n = 133). This left 50 articles for inclusion. Forty articles included in the 2009 guidelines were reviewed by 2 panel members and 19 were selected for inclusion, for a total of 69 articles.

An updated literature search was completed to identify additional relevant articles published between February 15, 2019, and August 1, 2022. The initial search after duplicates were removed yielded 128 articles. The abstracts and full-text articles were reviewed following the same process as the first literature review, which resulted in 13 articles being added to the systematic review (Figure). The primary findings of the systematic review are summarized in Tables 1–7. Additional data are presented in eTables 1 and 2.

As detailed in the AAN's guideline development process manual, a modified version of the Grading of Recommendations

Table 1 Unadjusted Prevalence of Any MCM by ASM in Monotherapy or Polytherapy

ASM	Mono or polytherapy	Total sample size	<i>I</i> ²	Included studies	Prevalence per 1,000 (95% CI)	Difference in prevalence between monotherapy and polytherapy (95% CI)
Carbamazepine	Monotherapy	9,908	69.6	2 Class I, ^{6,7} 6 Class II, ⁸⁻¹³ 11 Class III ¹⁴⁻²⁴	43.7 (35.7–52.6)	–14.9 (–38.1 to 8.3) Low confidence in evidence
	Polytherapy	1,231	59.3	3 Class II, ^{8,10,12} 5 Class III ^{17,18,20,25,26}	58.6 (38.8–82.1)	
Clobazam	Monotherapy	64	0	1 Class II ¹¹	31.3 (0.5–91.9)	–5.8 (–82.4 to 70.8) Very low confidence in evidence, downgraded for imprecision
	Polytherapy	27	0	1 Class II ¹⁰	37.0 (29.2–152.2)	
Clonazepam	Monotherapy	187	26.5	3 Class III ^{15,18,22}	30.3 (7.4–67.8)	–56.2 (–113.3 to 1.0) Very low confidence in evidence, downgraded for imprecision and not further upgraded for magnitude of effect
	Polytherapy	126	0.0	1 Class II, ¹⁰ 2 Class III ^{17,18}	86.4 (44.1–141.1)	
Ethosuximide	Monotherapy	NA	NA	NA	NA	NA
	Polytherapy	35	NA	1 Class II ¹⁰	28.6 (22.4–118.6)	
Gabapentin	Monotherapy	90	0.0	2 Class II ^{27,28}	30.9 (5.5–76.1)	NA
	Polytherapy	NA	NA	NA	NA	
Lamotrigine	Monotherapy	10,746	49.4	2 Class I, ^{6,7} 4 Class II, ^{11-13,27} 8 Class III ^{15,18,19,22-24,29,30}	30.7 (25.4–36.4)	–13.9 (–26.4 to –1.4) Low confidence in evidence
	Polytherapy	1,421	4.8	1 Class II, ¹² 4 Class III ^{18,25,26,29}	44.6 (34.1–56.5)	
Levetiracetam	Monotherapy	2,248	77.8	1 Class I, ⁶ 3 Class II, ^{11,27,31} 6 Class III ^{18,24,30,32-34}	34.8 (19.5–54.3)	–29.7 (–73.7 to 14.2) Low confidence in evidence, upgraded for magnitude of effect
	Polytherapy	605	67.0	1 Class II, ³¹ 3 Class III, ^{18,30,33} 2 Class IV ^{35,36}	64.5 (30.1–110.8)	
Oxcarbazepine	Monotherapy	1,036	0.0	1 Class I, ⁶ 2 Class II, ^{11,27} 2 Class III ^{18,24}	31.3 (21.6–42.8)	–17.6 (–45.7 to 10.5) Low confidence in evidence
	Polytherapy	262	0.0	1 Class II, ¹⁰ 1 Class III ¹⁸	48.9 (26.2–78.2)	
Phenobarbital	Monotherapy	1,116	0.0	1 Class I, ⁶ 3 Class II, ⁹⁻¹¹ 5 Class III ^{14,18,20,21,24}	60.3 (47.1–75.0)	16.9 (–8.8 to 42.6) Low confidence in evidence
	Polytherapy	341	0.0	1 Class II, ¹⁰ 1 Class III ¹⁷	43.4 (24.4–67.5)	
Phenytoin	Monotherapy	1,604	52.3	2 Class I, ^{6,7} 4 Class II, ^{9-11,28} 8 Class III ^{14-17,20-22,24}	51.3 (35.9–69.2)	13.3 (–13.4 to 40.1) Low confidence in evidence
	Polytherapy	318	0.0	1 Class II, ¹⁰ 2 Class III ^{17,26}	38.0 (19.8–61.7)	
Primidone	Monotherapy	99	0.0	3 Class III ^{14,20,21}	101.5 (50.4–167.7)	NA
	Polytherapy	NA	NA	NA	NA	
Topiramate	Monotherapy	748	0.0	1 Class I, ⁶ 3 Class II, ^{11,27,28} 2 Class III ^{15,18}	44.5 (30.9–60.4)	–26.9 (–110.2 to 56.3) Very low confidence in evidence, downgraded for imprecision
	Polytherapy	42	NA	1 Class III ¹⁸	71.4 (9.3–17.2)	
Valproic acid	Monotherapy	5,658	67.0	2 Class I, ^{6,7} 5 Class II, ^{8,10-13} 12 Class III ^{14,15,17-24,34,37}	96.7 (80.4–114.2)	–5.1 (–32.6 to 22.5) Low confidence in evidence
	Polytherapy	1,262	34.8	4 Class II, ^{8,10,12,38} 6 Class III ^{17-20,24,39}	101.7 (81.0–124.5)	
Zonisamide	Monotherapy	116	87.7	1 Class II, ¹¹ 1 Class III ⁴⁰	39.2 (11.7–236.1)	–18.9 (–142.3 to 104.4) Very low confidence in evidence, downgraded for imprecision
	Polytherapy	86	0.0	1 Class III ⁴⁰	58.1 (16.7–119.3)	

Abbreviations: ASM = antiseizure medication; *I*² = a statistical measure of study heterogeneity; MCM = major congenital malformation; NA = not applicable. No data were available for acetazolamide, brivaracetam, eslicarbazepine acetate, lacosamide, nitrazepam, perampanel, piracetam, pregabalin, rufinamide, stiripentol, tiagabine, or vigabatrin.

Assessment, Development and Evaluation process was used to develop conclusions after the analysis of evidence.⁵ The evidence was analyzed based on parameters pertaining to risk of bias,

consistency, directness, precision, and publication bias, providing transparency of the classification of evidence. As all comparisons included indirect data (comparisons between results reported in

Table 2 Unadjusted Prevalence Differences of Any MCM Across ASMs in Monotherapy

ASM		Carbamazepine	Clobazam	Clonazepam	Gabapentin	Lamotrigine	Levetiracetam	Oxcarbazepine	Phenobarbital	Phenytoin	Primidone	Topiramate	Valproic acid	Zonisamide	
	Prevalence per 1,000	43.7	31.3	30.2	30.9	30.7	34.8	31.3	60.3	51.3	101.5	44.5	96.7	39.2	
	95% CI	35.6–52.6	0.5–91.9	7.4–67.8	5.5–76.1	25.4–36.4	19.5–54.3	21.6–42.8	47.1–75.0	35.9–69.2	50.4–167.7	30.9–60.4	80.4–114.2	11.7–236.1	
Carbamazepine	43.7	35.6–52.6	X	–12.5 (–58.9 to 34) Low confidence	–13.5 (–44.9 to 17.9) Low confidence	–12.8 (–49.1 to 23.5) Low confidence	–13 (–23.1 to –2.9) Low confidence	–8.9 (–28.3 to 10.5) Low confidence	–12.4 (–26 to 1.2) Low confidence	16.6 (0.3 to 32.9) Low confidence	7.6 (–11.1 to 26.3) Low confidence	57.8 (–1.5 to 117.1) Very low confidence	0.8 (–16.2 to 17.8) Low confidence	53 (34.1–71.9) Moderate confidence	–4.5 (–117 to 108) Very low confidence
Clobazam	31.3	0.5–91.9	X	–1.1 (–55.8 to 53.7) Very Low confidence	–0.4 (–58.1 to 57.4) Very low confidence	–0.6 (–46.6 to 45.5) Low confidence	3.5 (–45.3 to 52.4) Low confidence	0.1 (–46.8 to 46.9) Low confidence	29 (–18.7 to 76.8) Low confidence	20 (–28.6 to 68.7) Low confidence	70.2 (–4.1 to 144.6) Very low confidence	13.2 (–34.8 to 61.3) Low confidence	65.4 (16.7–114.2) Moderate confidence	8 (–113.2 to 129.1) Very low confidence	
Clonazepam	30.2	7.4–67.8		X	0.7 (–45.8 to 47.2) Low confidence	0.5 (–30.2 to 31.2) Low confidence	4.6 (–30.3 to 39.5) Low confidence	1.1 (–30.9 to 33.1) Low confidence	30.1 (–3.2 to 63.4) Low confidence	21.1 (–13.4 to 55.6) Low confidence	71.3 (5.3–137.3) Very low confidence	14.3 (–19.3 to 47.9) Low confidence	66.5 (31.9–101.1) Moderate confidence	9 (–107.2 to 125.2) Very low confidence	
Gabapentin	30.9	5.5–76.1			X	–0.2 (–35.9 to 35.5) Low confidence	3.9 (–35.5 to 43.3) Low confidence	0.4 (–36.5 to 37.3) Low confidence	29.4 (–8.6 to 67.4) Low confidence	20.4 (–18.6 to 59.4) Low confidence	70.6 (2.1–139.1) Very low confidence	13.6 (–24.7 to 51.9) Low confidence	65.8 (26.7–104.9) Moderate confidence	8.3 (–109.3 to 125.9) Very low confidence	
Lamotrigine	30.7	25.4–36.4				X	4.1 (–14.1 to 22.3) Low confidence	0.6 (–11.3 to 12.5) Low confidence	29.6 (14.6–44.6) Low confidence	20.6 (3.1–38.1) Low confidence	70.8 (11.9–129.7) Very low confidence	13.8 (–1.9 to 29.5) Low confidence	66 (48.2–83.8) Moderate confidence	8.5 (–103.8 to 120.8) Very low confidence	
Levetiracetam	34.8	19.5–54.3					X	–3.5 (–23.9 to 16.9) Low confidence	25.5 (3.2–47.8) Low confidence	16.5 (–7.6 to 40.6) Low confidence	66.7 (5.5–127.9) Very low confidence	9.7 (–13.1 to 32.5) Low confidence	61.9 (37.6–86.2) Moderate confidence	4.4 (–109.1 to 117.9) Very low confidence	
Oxcarbazepine	31.3	21.6–42.8						X	29 (11.5–46.5) Low confidence	20 (0.3–39.7) Low confidence	70.2 (10.6–129.8) Very low confidence	13.2 (–5 to 31.4) Low confidence	65.4 (45.5–85.3) Moderate confidence	7.9 (–104.8 to 120.6) Very low confidence	
Phenobarbital	60.3	47.1–75.0							X	–9 (–30.7 to 12.7) Low confidence	41.2 (–19.1 to 101.5) Very low confidence	–15.8 (–36.1 to 4.5) Low confidence	36.4 (14.5–58.3) Low confidence	–21.1 (–134.2 to 92) Very low confidence	
Phenytoin	51.3	35.9–69.2								X	50.2 (–10.8 to 111.2) Very low confidence	–6.8 (–29 to 15.4) Low confidence	45.4 (21.7–69.1) Low confidence	–12.1 (–125.5 to 101.3) Very low confidence	
Primidone	101.5	50.4–167.7									X	–57 (–117.5 to 3.5) Very low confidence	–4.8 (–65.8 to 56.2) Very low confidence	–62.3 (–188.9 to 64.3) Very low confidence	
Topiramate	44.5	30.9–60.4										X	52.2 (29.8–74.6) Moderate confidence	–5.3 (–118.5 to 107.9) Very low confidence	
Valproic acid	96.7	80.4–114.2											X	–57.5 (–171 to 56) Very low confidence	

Abbreviations: ASM = antiseizure medication; MCM = major congenital malformation.
Prevalence difference = row – column.
Bold values are statistically significant.

Table 3 Unadjusted Prevalence of Specific MCM, by Individual ASMs in Monotherapy

ASM	Total sample size	I ²	Included studies	Prevalence per 1,000 (95% CI)	Difference in prevalence compared with reference (95% CI)
Brain					
Carbamazepine	1,028	48.5	1 Class II, ¹² 1 Class III ¹⁸	1.5 (0.0–6.8)	–24.1 (–104.9 to –3.7) Very low confidence in evidence, downgraded for imprecision and not further upgraded for magnitude of effect
Lamotrigine	4,548	0.0	1 Class I, ⁷ 2 Class II, ^{12,27} 4 Class III ^{18,29,41,42}	2.8 (1.5–4.5)	–22.8 (–103.6 to –2.9) Very low confidence in evidence, downgraded for imprecision and not further upgraded for magnitude of effect
Phenytoin	56	NA	1 Class I ⁷	27.4 (1.3–85.4)	Reference
Valproic acid	616	0.0	1 Class I, ⁷ 1 Class II, ¹² 1 Class III ¹⁸	8.0 (2.5–16.5)	–17.6 (–98.5 to 4.9) Very low confidence in evidence, downgraded for imprecision and not further upgraded for magnitude of effect
Neural tube					
Carbamazepine	3,874	50.0	2 Class II, ^{11,28} 5 Class III ^{17,20,22,24,43}	5.6 (2.6–9.7)	–8.7 (–15.1 to –2.3) Moderate confidence in evidence, upgraded for magnitude of effect
Lamotrigine	2,355	43.5	2 Class II, ^{11,28} 3 Class III ^{24,41,43}	3.4 (0.4–9.2)	–11.0 (–17.8 to –4.1) Moderate confidence in evidence, upgraded for magnitude of effect
Levetiracetam	556	0.0	1 Class II, ¹¹ 1 Class III ²⁴	3.1 (0.2–9.3)	–11.3 (–18.3 to –4.2) Moderate confidence in evidence, upgraded for magnitude of effect
Oxcarbazepine	71	0.0	1 Class III ²⁴	3.5 (3.2 to –30.3)	–10.8 (–25.4 to 3.7) Very low confidence in evidence
Phenobarbital	384	0.0	1 Class II, ¹¹ 2 Class III ^{20,24}	4.1 (0.2–12.9)	–10.2 (–18.5 to –1.9) Moderate confidence in evidence, upgraded for magnitude of effect
Phenytoin	758	0.0	2 Class II, ^{11,28} 2 Class III ^{20,24}	2.0 (0.1–6.4)	–12.3 (–18.5 to –6.1) Moderate confidence in evidence, upgraded for magnitude of effect
Primidone	43	NA	1 Class III ²⁰	10.6 (2.1–62.1)	–3.7 (–34.2 to 26.8) Very low confidence in evidence, 1 Class III study
Topiramate	359	NA	1 Class II ¹¹	1.3 (0.2–7.7)	–13.0 (–19.5 to –6.5) Moderate confidence in evidence, upgraded for magnitude of effect
Valproic acid	3,578	31.9	3 Class II, ^{11,44,45} 5 Class III ^{17,20,22,24,43}	14.3 (9.5–20.1)	Reference
Cardiac					
Carbamazepine	5,211	70.8	4 Class II, ^{10–12,28} 6 Class III ^{17,18,20,22,24,43}	8.5 (4.8–13.2)	–33.4 (–52.7 to –14.1) Moderate confidence in evidence, upgraded for magnitude of effect
Lamotrigine	6,179	87.0	1 Class I, ⁷ 4 Class II, ^{11,12,27,28} 5 Class III ^{18,24,29,41,43}	16.6 (7.8–28.5)	–25.3 (–46.8 to –3.8) Moderate confidence in evidence, upgraded for magnitude of effect
Levetiracetam	556	81.3	1 Class II, ¹¹ 1 Class III ²⁴	12.5 (0.1–53.4)	–29.4 (–62.0 to 3.2) Low confidence in evidence, upgraded for magnitude of effect
Oxcarbazepine	71	0.0	1 Class III ²⁴	42.3 (5.4–104.3)	0.4 (–52.6 to 53.3) Very low confidence in evidence
Phenobarbital	432	0.0	2 Class II, ^{10,11} 2 Class III ^{20,24}	41.9 (25.1–62.7)	Reference
Phenytoin	955	6.5	1 Class I, ⁷ 3 Class II, ^{10,11,28} 2 Class III ^{20,24}	19.9 (11.6–30.3)	–22.0 (–43.0 to –1.0) Moderate confidence in evidence, upgraded for magnitude of effect

Continued

Table 3 Unadjusted Prevalence of Specific MCM, by Individual ASMs in Monotherapy (continued)

ASM	Total sample size	I^2	Included studies	Prevalence per 1,000 (95% CI)	Difference in prevalence compared with reference (95% CI)
Primidone	147	0.0	1 Class II, ¹⁰ 2 Class III ^{17,20}	11.6 (0.8–35.1)	–8.2 (–27.8 to 11.3) Low confidence in evidence, upgraded for magnitude of effect
Topiramate	359	0.0	1 Class II ¹¹	2.8 (2.1 to –11.9)	–39.1 (–58.5 to –19.6) High confidence in evidence, upgraded twice for magnitude of effect
Valproic acid	2,212	66.2	1 Class I, ⁷ 5 Class II, ^{10–12,44,45} 6 Class III ^{17,18,20,21,24,43}	25.1 (16.9–35.0)	–16.8 (–37.6 to 4.1) Low confidence in evidence
Oral and cleft palate					
Carbamazepine	4,103	27.8	3 Class II, ^{10,11,28} 5 Class III ^{17,20,22,43,46}	4.7 (2.5–7.6)	–17.6 (–37.0 to 1.8) Low confidence in evidence
Lamotrigine	8,052	84.4	4 Class II, ^{11,27,28,47} 4 Class III ^{29,43,46,48}	4.6 (1.3–9.9)	–17.7 (–37.4 to 2.0) Low confidence in evidence
Levetiracetam	450	0.0	1 Class II ¹¹	0.0 (0.0–3.8)	–22.3 (–41.6 to –3.0) High confidence in evidence, upgraded twice for large magnitude of effect
Phenobarbital	295	14.3	2 Class II, ^{10,11} 1 Class III ²⁰	22.3 (7.1–45.6)	Reference
Phenytoin	904	0.0	3 Class II, ^{10,11,28} 2 Class III ^{17,20}	9.7 (4.4–17.2)	–12.6 (–32.8 to 7.7) Low confidence in evidence
Primidone	86	0.4	1 Class II, ¹⁰ 1 Class III ²⁰	16.6 (0.6–54.1)	–5.7 (–38.6 to 27.3) Low confidence in evidence
Topiramate	846	0.0	2 Class II ^{13,47}	14.1 (7.3–23.1)	–8.2 (–29.0 to 12.6) Low confidence in evidence
Valproic acid	3,636	27.8	4 Class II, ^{10,11,44,45} 5 Class III ^{17,20,22,43,46}	8.0 (4.6–12.2)	–14.3 (–34.0 to 5.3) Low confidence in evidence
Urogenital					
Carbamazepine	1,033	NA	1 Class II ¹¹	1.4 (0.0–4.6)	–11.0 (–17.2 to –4.8) Moderate confidence in evidence, upgraded for magnitude of effect
Lamotrigine	3,203	80.3	1 Class II, ¹¹ 2 Class III ^{29,41}	2.0 (0.0–8.9)	–10.4 (–17.7 to –3.1) Moderate confidence in evidence, upgraded for magnitude of effect
Levetiracetam	450	0.0	1 Class II ¹¹	1.0 (0.2–6.1)	–11.4 (–17.9 to –4.9) High confidence in evidence, upgraded twice for very large magnitude of effect
Phenobarbital	199	0.0	1 Class II ¹¹	7.3 (0.3–23.8)	–5.2 (–18.2 to 7.9) Low confidence in evidence
Phenytoin	416	0.0	1 Class II ¹¹	1.1 (0.2–6.6)	–11.3 (–17.9 to –4.8) High confidence in evidence, upgraded twice for very large magnitude of effect
Topiramate	359	0.0	1 Class II ¹¹	7.2 (1.1–18.5)	–5.3 (–15.7 to 5.1) Low confidence in evidence
Valproic acid	1,432	0.0	2 Class II ^{11,45}	12.4 (7.4–18.8)	Reference
Renal					
Carbamazepine	2,841	3.6	1 Class II, ²⁸ 5 Class III ^{17,20,22,24,43}	5.5 (3.1–8.7)	–8.2 (–14.5 to –1.9) Moderate confidence in evidence, upgraded for magnitude of effect
Lamotrigine	2,354	41.9	1 Class II, ³⁰ 3 Class III ^{24,29,43}	6.6 (2.1–13.6)	–7.1 (–15.1 to 0.9) Low confidence in evidence
Levetiracetam	106	0.0	1 Class III ²⁴	9.4 (7.3–40.1)	–4.3 (–21.6 to 13.1) Very low confidence in evidence

Continued

Table 3 Unadjusted Prevalence of Specific MCM, by Individual ASMs in Monotherapy (continued)

ASM	Total sample size	I^2	Included studies	Prevalence per 1,000 (95% CI)	Difference in prevalence compared with reference (95% CI)
Oxcarbazepine	71	0.0	1 Class III ²⁴	14.1 (10.9–59.5)	0.4 (–24.6 to 24.3) Very low confidence in evidence
Phenobarbital	185	0.0	2 Class III ^{24,40}	2.5 (0.5–14.8)	–11.2 (–20.3 to –2.1) Moderate confidence in evidence, upgraded for magnitude of effect
Phenytoin	466	0.0	1 Class II, ²⁸ 3 Class III ^{17,20,24}	8.0 (2.0–18.1)	–5.7 (–15.5 to 4.1) Low confidence in evidence
Primidone	43	0.0	1 Class III ²⁰	0.0 (0.0–39.6)	–13.7 (–34.3 to 6.9) Very low confidence in evidence
Valproic acid	1,637	0.0	1 Class II, ²⁸ 5 Class III ^{17,20,22,24,43}	13.7 (8.6–19.9)	Reference

Abbreviations: ASM = antiseizure medication; I^2 = a statistical measure of study heterogeneity; MCM = major congenital malformation; NA = not applicable; RMD = raw mean difference.

different studies) and, at best, classified as Class III evidence to address causation, the initial confidence rating for most conclusions was anchored as low if at least 2 Class III or at least 1 Class I or II studies informed each estimate used in the comparisons. The initial confidence rating was set to very low if one of the contributing estimates was informed by a single Class III study.

In the second step, the classification of evidence was upgraded or downgraded according to criteria specified in the process manual (e.g., upgraded for large magnitude of effect, downgraded for lack of statistical precision).⁵ For estimates obtained through indirect comparisons, confidence in the evidence was downgraded for precision when the width of the 95% CI for any prevalence difference (PD) for MCMs or ASD was greater than 100 per 1,000 live births or greater than 300 per 1,000 live births for perinatal outcomes. Confidence was also downgraded for precision when the width of the 95% CI

raw mean difference (RMD) for IQ was greater than 20 points. For indirect comparisons, although we present the PD in the synthesis of evidence and conclusions, our assessment of magnitude of effect was based on the corresponding prevalence ratio (PR). Confidence in the evidence was upgraded by 1 level for large magnitude of effect if the calculated PR was greater than 2 or lower than 0.5. Confidence in the evidence was upgraded by 2 levels for very large magnitude of effect if the calculated PR was greater than 10 or lower than 0.1. Confidence in the evidence was upgraded by 1 level for large magnitude of effect for IQ if the RMD was greater than 10 points and by 2 levels if greater than 20 points. For estimates drawn from adjusted PR (relevant to the perinatal and neurodevelopmental outcomes), confidence in evidence was downgraded for precision if the width of the CI was greater than 2. If the confidence in the evidence was very low, it was not upgraded for other factors. Estimates not reaching

Table 4 Global IQ With Exposure to ASM Monotherapy

ASM	Total sample size	I^2	Included studies	Global IQ mean (95% CI)	RMD compared with reference (95% CI)
Carbamazepine	316	86.0	2 Class I, ^{50,51} 4 Class III ⁵²⁻⁵⁵	100.4 (95.8–105.1)	6.53 (0.39–12.67) Low confidence in evidence
Lamotrigine	129	77.0	1 Class I, ⁵¹ 1 Class III ⁵⁵	105.8 (100.9–110.6)	11.85 (5.53–18.15) Moderate confidence in evidence, upgraded for magnitude of effect
Levetiracetam	42	NA	1 Class III ⁵⁶	99.0 (95.0–103.0)	6.3 (0.9–11.7) Very low confidence in evidence
Phenytoin	76	84.8	1 Class I, ⁵¹ 1 Class III ⁵³	103.2 (93.0–113.4)	9.29 (–1.63 to 20.21) Very low confidence in evidence, downgraded for imprecision
Topiramate	27	NA	1 Class III ⁵⁶	100.5 (95.8–105.2)	6.58 (0.37–12.80) Very low confidence in evidence
Valproic acid	173	69.0	2 Class I, ^{50,51} 2 Class III ^{53,56}	93.9 (89.1–97.9)	Reference

Abbreviations: ASM = antiseizure medication; I^2 = a statistical measure of study heterogeneity; NA = not applicable; RMD = raw mean difference.

Table 5 Verbal and Non-Verbal IQ With Exposure to ASM Monotherapy

ASM	Total sample size	I^2	Included studies	Mean verbal or non-verbal IQ (95% CI)	RMD compared with reference (95% CI)
Verbal IQ					
Carbamazepine	283	82.0	2 Class I, ^{50,51} 3 Class III ^{52,53,55}	98.4 (94.6–102.2)	6.3 (–0.2 to 12.8) Low confidence in evidence
Lamotrigine	103	79.0	1 Class I, ⁵¹ 1 Class III ⁵⁵	102.4 (96.5–108.2)	10.3 (2.4–18.2) Moderate confidence in evidence ^a
Levetiracetam	42	NA	1 Class III ⁵⁶	101.0 (97.7–104.3)	8.9 (2.7–15.1) Very low confidence in evidence
Phenytoin	61	69.2	1 Class I, ⁵¹ 1 Class III ⁵³	103.0 (95.8–110.2)	10.9 (2.0–19.8) Moderate confidence in evidence ^a
Topiramate	27	NA	1 Class III ⁵⁶	99.2 (95.2–103.2)	7.1 (0.5–13.7) Very low confidence in evidence
Valproic acid	160	83.0	2 Class I, ^{50,51} 2 Class III ^{53,56}	92.1 (86.9–97.4)	Reference
Non-verbal IQ					
Carbamazepine	197	53.9	1 Class I, ⁵¹ 2 Class III ^{52,55}	104.7 (102.2–107.3)	3.6 (0.0–7.1) Low confidence in evidence
Lamotrigine	103	75.5	1 Class I, ⁵¹ 1 Class III ⁵⁵	105.8 (100.9–110.7)	4.6 (–0.8 to 10.1) Low confidence in evidence
Levetiracetam	42	NA	1 Class III ⁵⁶	99.6 (95.5–103.7)	–1.6 (–6.3 to 3.2) Very low confidence in evidence
Phenytoin	40	NA	1 Class I ⁵¹	106.0 (103.1–109.0)	4.8 (0.1–8.7) Low confidence in evidence
Topiramate	27	NA	1 Class III ⁵⁶	102.4 (97.1–107.7)	1.2 (–4.6 to 7.1) Very low confidence in evidence
Valproic acid	96	0.0	1 Class I, ⁵¹ 1 Class III ⁵⁶	101.2 (98.7–103.6)	Reference

Abbreviations: ASM = antiepileptic medication; I^2 = a statistical measure of study heterogeneity; NA = not applicable; RMD = raw mean difference.
^a Items were upgraded for large magnitude of effect.

Table 6 Unadjusted Prevalence of ASD, PDD, or ASD Traits by ASM Monotherapy

ASM	Total sample size	I^2	Included studies	Prevalence per 1,000 of ASD/ASD risk (95% CI)	Difference in prevalence compared with reference (95% CI)
Carbamazepine	4,493	84.9	1 Class II, ⁵⁷ 4 Class III ^{49,58-60}	17.1 (6.2–33.1)	–24.9 (–41.5 to –8.2) Moderate confidence, upgraded for large magnitude of effect
Clonazepam	587	51.7	1 Class II, ⁵⁷ 1 Class III ⁴⁹	20.8 (7.5–40.7)	–21.1 (–40.4 to –1.8) Moderate confidence in evidence, upgraded for large magnitude of effect
Lamotrigine	7,568	66.5	1 Class II, ⁵⁷ 5 Class III ^{49,58-60}	14.5 (8.6–22.2)	–27.4 (–39.3 to –15.6) Moderate confidence in evidence, upgraded for large magnitude of effect
Levetiracetam	1,226	56.0	2 Class III ^{49,e1}	11.3 (2.9–25.1)	–30.6 (–45.4 to –15.8) Moderate confidence in evidence, upgraded for large magnitude of effect
Oxcarbazepine	321	NA	1 Class II ⁵⁷	23.3 (9.7–42.6)	–18.6 (–37.8 to 0.5) Low confidence in evidence
Valproic acid	3,399	36.7	1 Class II, ⁵⁷ 4 Class III ^{49,58,60,e1}	41.9 (32.7–52.3)	Reference

Abbreviations: ASD = autism spectrum disorder; ASM = antiepileptic medication; I^2 = a statistical measure of study heterogeneity; NA = not applicable; PDD = pervasive developmental disorder.

Table 7 Unadjusted Prevalence of SGA by ASM Monotherapy

ASM	Total sample size	<i>I</i> ²	Included studies	Prevalence per 1,000 (95% CI)	Difference in prevalence compared with reference (95% CI)
Carbamazepine	3,033	96.3	1 Class II, ^{e32} 5 Class III ^{46,e33-e36}	75.7 (31.3–137.5)	–4.4 (–153.9 to 145.0) Low confidence in evidence
Clobazam	30	0.0	1 Class III ^{e33}	177.1 (64.6–329.9)	96.9 (–95.7 to 289.6) Very low confidence in evidence
Clonazepam	276	NA	2 Class III ^{e33,e36}	165.4 (123.0–212.7)	85.2 (–61.5 to 231.9) Low confidence in evidence
Gabapentin	225	91.3	2 Class III ^{e33,e36}	58.5 (0.1–214.2)	–21.7 (–197.7 to 154.3) Low confidence in evidence
Lamotrigine	2,597	98.0	1 Class I, ^{e37} 1 Class II, ^{e32} 5 Class III ^{44,e33-e36}	85.1 (13.6–209.6)	5.0 (–165.7 to 175.6) Low confidence in evidence
Levetiracetam	835	85.2	1 Class I, ^{e37} 2 Class III ^{e33,e38}	52.9 (6.8–138.6)	–27.3 (–181.7 to 127.1) Low confidence in evidence
Oxcarbazepine	1,045	96.1	3 Class III ^{e33,e34,e38}	58.0 (6.8–154.2)	–22.2 (–180.1 to 135.7) Low confidence in evidence
Phenobarbital	274	95.3	2 Class III ^{e33,e36}	89.3 (0.3–310.0)	9.1 (–199.4 to 217.6) Low confidence in evidence
Phenytoin	464	24.5	3 Class III ^{e34-e36}	14.4 (2.7–35.1)	–65.8 (–206.3 to 74.8) Low confidence in evidence
Primidone	20	0.0	1 Class III ^{e33}	166.0 (40.7–352.9)	85.8 (–123.6 to 295.2) Very low confidence in evidence
Topiramate	453	93.6	2 Class III ^{e33,e38}	80.2 (0.3–279.6)	Reference
Valproic acid	1,829	97.6	1 Class II, ^{e32} 7 Class III ^{35,46,e33-e35,e38}	147.1 (53.9–276.0)	66.9 (–111.5 to 245.4) Low confidence in evidence
Zonisamide	125	NA	1 Class III ^{e36}	20.4 (3.1–52.4)	–59.7 (–201.6 to 82.1) Low confidence in evidence

Abbreviations: ASM = antiepileptic medication; *I*² = a statistical measure of study heterogeneity; NA = not applicable; SGA = small for gestational age.

statistical significance were not upgraded for magnitude of effect.

The authors formulated a rationale for each recommendation based on the evidence systematically reviewed and stipulated axiomatic principles of care, related evidence, and inferences. The recommendation development process is described in further detail in the complete guideline (eAppendix 1) and the AAN’s guideline development process manual.⁵

Clinical Context

The goal of this guideline is to assist clinicians (e.g., physicians, nurses, and advanced practice providers) in the pharmacologic management of PWECP to limit risk of adverse congenital, perinatal, and neurodevelopmental outcomes. Given the many variables that may confound the outcomes we examined (e.g., genetic conditions, pregnancy conditions, and socioeconomic contexts), we weighted evidence more strongly where analyses could be adjusted for these and other potential confounders (i.e., Class I studies). Demonstration of

a dose effect can further support a causal relationship between an exposure and an outcome. Although our preplanned analyses using external comparisons could not reach a level of evidence sufficient to drive recommendations, a statistically and clinically important difference in prevalence of MCMs was found for valproic acid and phenobarbital between high and low-dose exposures (eTable 1). The only Class I study addressing this question from EURAP demonstrated a dose effect for carbamazepine, lamotrigine, phenobarbital, and valproic acid.⁶ To reduce the risk of MCMs, it is reasonable practice to use the lowest appropriate dose of ASMs in PWECP, if clinically feasible.

The available evidence on the association between in utero ASM exposure and neurodevelopmental outcomes is rapidly expanding. Although valproic acid exposure shows a strong effect, data from our preplanned analyses on adverse neurodevelopmental outcomes were insufficient to demonstrate an effect; thus, caution in counseling is warranted. While we could not extract sufficient data on topiramate exposure, the SCAN-AED study⁴⁹ found even higher prevalences of ASD and intellectual disability with exposure to topiramate than

valproic acid. Their adjusted hazard ratios (aHRs), however, used prevalence in the general population of children as a comparator group (aHRs for ASD and intellectual disability after topiramate exposure were 2.8 [95% CI 1.4–5.7] and 3.5 [95% CI 1.4–8.6], respectively). Further studies are needed to replicate these findings and examine these outcomes across other ASMs.

Folic acid prescribing practices for PWECP are variable.^{e2,e3} One much anticipated outcome from the current systematic review was clarification of the optimal folic acid dosage to reduce potential negative effects of ASMs in pregnancy. As discussed, the data do not find that folic acid supplementation reduces the risk of MCMs among PWECP. However, improved neurocognitive outcomes have been observed in offspring of PWECP who received folic acid supplementation before and throughout pregnancy. The analysis does not support a more specific dosage recommendation beyond at least 0.4 mg/d. There is limited evidence from a published analysis of 27,784 children born to people with epilepsy that exposure to periconceptional folic acid ≥ 1 mg/d was associated with a 0.9% absolute increase in the risk of childhood cancer before age 20 years, resulting in an HR of 2.7 (95% CI 1.2–6.3). Subanalysis restricted to exposure to maternal epilepsy and supplemental folic acid doses < 3 mg/d was not significant when compared with maternal epilepsy without a prescription for high-dose folic acid (aHR 2.6, 95% CI 1.0–6.9).^{e4} A study of 1,257 mother-child pairs from the general population found that very high maternal serum folic acid concentrations (≥ 60.3 nmol/L) at birth had a 2.5 times increased risk of ASD (95% CI 1.3–4.6) compared with those with lower folic acid concentrations.^{e5} These results are concerning, but the studies have limitations, including their high risk of confounding by indication. The dose chosen should balance demonstrated benefits of supplementation and potential negative consequences of high doses. Future well-designed (preferably randomized) studies are needed to better define optimal folic acid dosing for PWECP.

Practice Recommendations

General

Recommendation 1 Rationale

The overarching goals of care for PWECP are to optimize health outcomes both for individuals and their future offspring. In many cases, in utero ASM exposure may be associated with increased risks to the fetus. There are also risks associated with discontinuing or changing ASMs in PWECP.^{53,e6-e8} A shared decision-making process leads to more informed choices, a better understanding of available options, a more accurate risk perception, and improved decision quality grounded in individual values.^{e9} This decision-making process may take into account an individual's plans for pregnancy. However, according to the Epilepsy Birth Control Registry of 1,114 PWECP in the United States, more than 65% of pregnancies

among PWECP are unintended.^{e10,e11} The ASM regimen used for a PWECP when pregnancy is not planned is thus very often the regimen used at the time of conception.

Recommendation 1 Statements

1(A) Clinicians should engage in joint decision-making with PWECP, taking individual preferences into account when selecting ASMs and monitoring their dosing (Level B).

1(B) When treating PWECP, clinicians should recommend ASMs and doses that optimize both seizure control and fetal outcomes should pregnancy occur, at the earliest possible opportunity preconceptionally (e.g., at the time of starting an ASM in a person post-menarche) (Level B).

Recommendation 2 Rationale

The odds of mortality during pregnancy is 5–12 times greater among PWECP as compared with pregnant people without epilepsy, according to an analysis of a Danish cohort of more than 2 million pregnancies and a US cohort of more than 20 million participants.^{e12,e13} Among 202 pregnancy-related deaths in the United Kingdom from 2013 to 2015, most of the 13 epilepsy-related deaths were from sudden unexpected death in epilepsy. All participants with prepregnancy data had uncontrolled seizures. Five of the participants who died had stopped taking their ASMs during pregnancy.^{e14}

In an analysis of the EURAP study including 1,956 pregnancies among 1,882 participants, there was no statistical association between seizures during pregnancy and spontaneous abortion or stillbirth. However, the 1 stillbirth that occurred soon after a seizure was an episode of convulsive status epilepticus.^{e15} The frequency of generalized tonic-clonic seizures or focal-to-bilateral tonic-clonic seizures may also be a risk factor of lower IQ in children born to PWECP.⁵³

Valproic acid is one of the most effective ASMs at obtaining adequate seizure control among people with idiopathic generalized epilepsy.^{e7,e8} An analysis of the EURAP cohort of PWECP treated with valproic acid at the onset of pregnancy showed that generalized tonic-clonic seizures or focal-to-bilateral tonic-clonic seizures during pregnancy were twice as likely to occur when valproic acid was removed or replaced with another ASM, compared with when it was maintained throughout the pregnancy.^{e6}

The serum concentration of most ASMs has a defined therapeutic window for effective seizure control. The serum concentration of some ASMs (in particular, lamotrigine and levetiracetam) decreases during pregnancy. These decreases may occur at any point during the pregnancy.^{e16-e18}

There are limited data available on epilepsy-related outcomes during pregnancy among PWECP for numerous ASMs, including but not limited to acetazolamide, eslicarbazepine, ethosuximide, lacosamide, nitrazepam, perampanel, piracetam, pregabalin, rufinamide, stiripentol, tiagabine, and vigabatrin.

Recommendation 2 Statements

2A. Clinicians must minimize the occurrence of convulsive seizures (generalized tonic-clonic seizures and focal-to-bilateral tonic-clonic seizures) in PWECP during pregnancy to minimize potential risks to the birth parent (e.g., seizure-related mortality) and to the fetus (Level A).

2B. Once a PWECP is already pregnant, clinicians should exercise caution in attempting to remove or replace an ASM that is effective in controlling generalized tonic-clonic or focal-to-bilateral tonic-clonic seizures, even if it is not an optimal choice with regards to the risk to the fetus (e.g., valproic acid) (Level B).

2C. Clinicians should monitor ASM levels in PWECP throughout pregnancy as guided by individual ASM pharmacokinetics and patient clinical presentation (Level B).

2D. Clinicians should adjust the dose of ASMs at their clinical discretion during the pregnancy in response to (1) decreasing serum ASM levels or (2) worsening seizure control (observed or anticipated based on the clinician's judgment and known pharmacokinetics of ASMs in the pregnant state) (Level B).

2E. Clinicians treating PWECP using acetazolamide, eslicarbazepine, ethosuximide, lacosamide, nitrazepam, perampanel, piracetam, pregabalin, rufinamide, stiripentol, tiagabine, or vigabatrin should counsel their patients that there are limited data on pregnancy-related outcomes for these drugs (Level B).

Antiseizure Medications: Major Congenital Malformations

Recommendation 3 Rationale

The unadjusted birth prevalence of any MCM among children born to people without epilepsy is approximately 2.4%–2.9%.^{e19} Of the ASMs with sufficient numbers of exposures to draw reliable conclusions (greater than 1,000 exposures), lamotrigine, levetiracetam, and oxcarbazepine are associated with the lowest unadjusted birth prevalence of any MCM in monotherapy (3.1%, 3.5%, and 3.1%, respectively) among children born to PWECP. Valproic acid exposure is associated with the highest unadjusted birth prevalence (9.7%) of any MCM among children born to PWECP as compared with other ASMs.

Valproic acid is associated with the highest unadjusted birth prevalence of neural tube defects (NTDs) (1.4%) as compared with other ASMs. Phenobarbital is associated with the highest unadjusted birth prevalence of cardiac malformations (4.4%) as compared with other ASMs. Phenobarbital and topiramate are associated with the highest unadjusted birth prevalence of oral and cleft palate (2.2% and 1.4% respectively) compared with other ASMs. Valproic acid is associated with the highest unadjusted birth prevalence of urogenital (1.2%) and renal (1.4%) malformations compared with other ASMs.

A detailed anatomical ultrasound of the fetus can enable earlier diagnosis of MCMs.^{e20-e24} Early detection of severe

congenital heart defects, especially those requiring surgery in the early postnatal period, has been shown to improve morbidity and mortality in affected newborns.^{e25-e28} Detection of MCMs can also inform an early pregnancy termination decision or guide perinatal management, including giving birth in specialized pediatric centers, while a normal ultrasound may offer reassurance to expecting parents. This needs to be balanced with differences in individual preferences.

Recommendation 3 Statements

3A. Clinicians must counsel their patients with epilepsy that the birth prevalence of any MCM in the general population is approximately 2.4%–2.9%, providing a comparison framework for their individual risk (Level A).

3B. Clinicians must consider using lamotrigine, levetiracetam, or oxcarbazepine in PWECP when appropriate based on the patient's epilepsy syndrome, likelihood of achieving seizure control, and comorbidities, to minimize the risk of MCMs (Level A).

3C. Clinicians must avoid the use of valproic acid in PWECP to minimize the risk of MCMs (composite outcome) or NTDs, if clinically feasible (Level A).

3D. Clinicians must counsel PWECP who are treated with, or are considering starting, valproic acid that the risk of any MCM is the highest with valproic acid as compared with other studied ASMs (Level A).

3E. To reduce the risk of cardiac malformations, clinicians must avoid the use of phenobarbital in PWECP, if clinically feasible (Level A).

3F. To reduce the risk of oral clefts, clinicians should avoid the use of phenobarbital and topiramate in PWECP, if clinically feasible (Level B).

3G. To reduce the risk of urogenital and renal malformations, clinicians should avoid the use of valproic acid in PWECP, if clinically feasible (Level B).

3H. To enable early detection and timely intervention of MCMs, obstetricians should recommend fetal screening for MCMs (e.g., a detailed anatomical ultrasound, where available) for PWECP who are treated with any ASM during pregnancy (Level B).

3I. To enable early detection and timely intervention of congenital heart defects, obstetricians should recommend screening cardiac investigations of the fetus among PWECP who are treated with phenobarbital during pregnancy (Level B).

Antiseizure Medications: Perinatal Outcomes

Recommendation 4 Rationale

Among children exposed to ASMs in utero and born to PWECP, the prevalence of intrauterine death is highly likely

not to differ across ASMs when used in monotherapy and the prevalence of prematurity is possibly no different across ASMs when used in monotherapy (eTable 2). The risk of intrauterine death is likely higher with polytherapy exposure compared with monotherapy exposure. Fetal growth restriction increases the risk of perinatal morbidity and mortality.^{e29,e30} The prevalence of children born SGA is possibly greater after exposure to valproic acid or topiramate compared with lamotrigine. Prenatal identification of fetuses at risk of being born SGA leads to improved perinatal outcomes by informing timely delivery.^{e31}

Recommendation 4 Statements

4A. Clinicians should counsel PWECP that the prevalence of intrauterine death does not differ among different ASM exposures in monotherapy (Level B).

4B. Clinicians should avoid the use of valproic acid or topiramate in PWECP to minimize the risk of offspring being born SGA, if clinically feasible (Level B).

4C. To enable early identification of fetal growth restriction, obstetricians should recommend screening of fetal growth throughout pregnancy among PWECP who are treated with valproic acid or topiramate (Level B).

Antiseizure Medications: Neurodevelopmental Outcomes

Recommendation 5 Rationale

Among children born to PWECP, in utero exposure to valproic acid is likely associated with a decrease in full scale IQ at age 6 years compared with gabapentin and lamotrigine in monotherapy; valproic acid is possibly associated with a decrease as compared with carbamazepine, levetiracetam, and topiramate in monotherapy; and there is possibly no difference in full scale IQ with valproic acid as compared with phenytoin in monotherapy.

Among children born to PWECP, in utero exposure to valproic acid is likely associated with a decrease in verbal IQ at age 6 years compared with gabapentin, lamotrigine, levetiracetam, and phenytoin in monotherapy, and possibly associated with a decrease as compared with carbamazepine and topiramate in monotherapy.

Among children born to PWECP, in utero exposure to valproic acid is possibly associated with a decrease in non-verbal IQ at age 6 years compared with carbamazepine and phenytoin in monotherapy, but there is possibly no difference as compared with gabapentin, lamotrigine, levetiracetam, and topiramate in monotherapy.

Among children born to PWECP, in utero exposure to valproic acid throughout the pregnancy is possibly associated with an increased risk of ASD and autistic traits compared with other studied ASMs (i.e., carbamazepine, clonazepam, lamotrigine, and levetiracetam) used in monotherapy.

Numerous ASMs have limited available data on neurodevelopmental outcomes. These neurodevelopmental outcomes are determined during both early and later stages of pregnancy.^{e39} Early screening for neurodevelopmental disorders in children enables early diagnosis, facilitating access to early interventions where available. Early interventions in children with neurodevelopmental disorders optimize developmental trajectories.

Recommendation 5 Statements

5A. To reduce the risk of poor neurodevelopmental outcomes, including ASD and lower IQ, in children born to PWECP, clinicians must avoid the use of valproic acid in PWECP, if clinically feasible (Level A).

5B. Clinicians must counsel PWECP who are treated with, or are considering starting, valproic acid that in utero exposure to valproic acid is likely or possibly associated with a decrease in full scale, verbal, and non-verbal IQ, as compared with other studied ASMs (i.e., carbamazepine, gabapentin, lamotrigine, levetiracetam, phenytoin, and topiramate) (Level A).

5C. Clinicians must counsel PWECP who are treated with, or are considering starting, valproic acid that in utero exposure to valproic acid is possibly associated with an increased risk of ASD as compared with other studied ASMs (i.e., carbamazepine, clonazepam, levetiracetam, and lamotrigine) (Level A).

5D. Clinicians should implement age-appropriate developmental screening in children exposed to any ASM in utero born to PWECP (Level B).

Folic Acid

Recommendation 6 Rationale

The optimal dosing and timing of folic acid supplementation are unknown in PWECP. There is likely no demonstrated benefit of folic acid supplementation (at least 0.4 mg/d) specifically for the prevention of MCMs in children born to PWECP. Randomized controlled trials conducted before widespread folic acid fortification of foods in the United States demonstrated a reduction in NTDs among the offspring of the general childbearing population receiving periconceptional multivitamin supplementation.^{e40} A systematic review of 14 studies of folic acid supplementation (up to 1 mg/d) among pregnant people in the general population (generally without epilepsy), including 1,053 participants (some being control participants without folic acid supplementation) estimated that folic acid supplementation of 0.2 mg/d (the United States' level of folic acid fortification) would reduce the risk of NTDs by 23%.^{e41} This protective effect was greater in pregnant people with an initial low serum folate concentration than in those with higher serum folate concentrations.^{e41} Although valproic acid exposure in utero is associated with the highest prevalence of NTDs, the teratogenic causal pathway is not exclusively through the disruption of folic acid metabolism.^{e42}

Preconception folic acid supplementation is possibly associated with better neurodevelopmental outcomes among children born to PWECP. Folic acid supplementation of at least 0.4 mg/d is possibly associated with reduced autistic traits at 3 years (OR 7.9, 95% CI 2.5–24.9) and likely associated with a higher global IQ (on average 6 points) at 6 years in children born to PWECP exposed to ASMs in utero. Lower plasma concentrations of folic acid at gestational weeks 17–19 among pregnant people with epilepsy exposed to ASMs is correlated with a higher risk of autistic traits at 3 years. Higher exposure levels of folic acid from diet and supplements is associated with statistically significant increases in IQ at age 6 years; this association is not seen among PWECP who only received dietary folic acid and not periconceptional folic acid supplements. Higher doses of folic acid supplementation result in higher serum concentrations of folic acid.^{e43,e44} There is inconclusive evidence for an increased risk of adverse events with folic acid supplementation for the PWECP and the child (e.g., increased occurrence of twins, asthma, masking vitamin B12 deficiency, new or worsening of preexisting neoplasia).^{e40,e45,e46} In a recent analysis of 27,784 children born to people with epilepsy, exposure to periconceptional folic acid greater than 1 mg/d was associated with a 0.9% absolute increase in the risk of childhood cancer before age 20 years, resulting in an HR of 2.7 (95% CI 1.2–6.3).^{e46} There are potential pharmacokinetic interactions where folic acid can decrease phenytoin serum concentrations.^{e47} Adherence to folic acid supplementation is generally poor among PWECP, even during pregnancy.^{e48} ASM polytherapy is associated with decreased folic acid adherence among PWECP.^{e49} In the United States, where there is no high-dose folic acid formulation, higher doses of folic acid require a large number of tablets, potentially reducing adherence to folic acid supplementation.

Recommendation 6 Statements

6A. Clinicians should prescribe at least 0.4 mg of folic acid supplementation daily preconceptionally and during pregnancy to any PWECP treated with an ASM to decrease the risk of NTDs in the offspring (Level B).

6B. Clinicians must prescribe at least 0.4 mg of folic acid supplementation daily preconceptionally and during pregnancy to any PWECP treated with an ASM to possibly improve neurodevelopmental outcomes such as ASD and global IQ in the offspring (Level A).

6C. Clinicians should counsel PWECP treated with an ASM that adherence to recommended folic acid supplementation preconceptionally and during pregnancy is important to minimize the risk of MCMs and poor neurodevelopmental outcomes (Level B).

Suggestions for Future Research

The findings of this systematic review highlight several knowledge gaps that should be addressed in future research to

optimize reproductive outcomes for PWECP. The risks of MCMs and adverse perinatal outcomes for newer and understudied ASMs (e.g., lacosamide, zonisamide, clobazam, and perampanel) require further research. Future guidelines should consider even newer ASMs, such as cenobamate and fenfluramine, which were not included in our search strategy. Longitudinal studies evaluating long-term neurodevelopmental outcomes in children with in utero exposure to ASMs other than valproic acid are necessary to inform ASM choice among PWECP, developmental screening requirements, and resource planning. The risk of MCMs, adverse perinatal outcomes, and adverse neurodevelopmental outcomes in polytherapy is a complex picture that merits further clarification. Importantly, an improved understanding of the pathophysiologic mechanisms underlying teratogenic effects of some ASMs will guide rational development of therapeutic strategies. Clarification of factors affecting the pharmacokinetics and pharmacodynamics of ASM metabolism in PWECP during pregnancy and postpartum will inform dosing regimens. Future studies should work to use more uniform definitions for exposures (e.g., high vs low doses of ASMs) and outcomes, as well as which adjustment variables are included in any multivariable analyses, to facilitate the discovery of important findings and their interpretation.

There is considerable practice variation in the dosing of folic acid supplementation. High-quality studies, including randomized controlled trials where possible, will be required to definitively clarify the optimal dose and timing with respect to conception.

The impact of screening for fetal anomalies and growth restriction on perinatal outcomes needs to be established. Clarification of the impact of socioeconomic status on pregnancy outcomes in PWECP will inform social service priorities. To better clarify the potentially diverse needs of underrepresented groups, future studies should work to include diverse ethnic and racial groups, people from low and middle-income countries, as well as transgender, nonbinary, and intersex PWECP. Altogether, these lines of research will help identify pregnancies at greatest risk of adverse outcomes and inform new, targeted interventions to improve parental, fetal, perinatal, and neurodevelopmental outcomes.

Disclaimer

Clinical practice guidelines, practice advisories, systematic reviews, and other guidance published by the American Academy of Neurology (AAN) and its affiliates are assessments of current scientific and clinical information provided as an educational service. The information (1) should not be considered inclusive of all proper treatments or methods of care or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does

not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgment of the treating provider because the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. The AAN provides this information on an “as is” basis and makes no warranty, expressed or implied, regarding the information. The AAN specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. AAN assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

Conflict of Interest

The American Academy of Neurology (AAN) is committed to producing independent, critical, and trustworthy clinical practice guidelines (CPGs) and evidence-based documents. Significant efforts are made to minimize the potential for conflicts of interest to influence the recommendations of this evidence-based document. Management and disclosure of document developer relationships is conducted in compliance with the 2017 AAN process manual section titled, “Implementing the AAN Conflict of Interest Policy for Guidelines and Case Definitions,” which can be viewed at aan.com.

Acknowledgment

Coauthor Sanjeev V. Thomas, MD, died February 4, 2024. The authors are grateful for his contributions to this guideline and to the field of neurology. The authors thank former lead developer Cynthia L. Harden, MD, for drafting the protocol and clinical questions and former AAN staff member Shannon Merillat, MLIS, for her assistance during the guideline development process.

Study Funding

This practice guideline was developed with financial support from the American Academy of Neurology (AAN). Authors who have served as AAN subcommittee members (A.M.P., M.O., S.W.R., D.K.D., J.F., K.S., M.K.), or as methodologists (M.O., D.B.S.), or who are or were AAN staff members (M.D.O., K.B.D., H.M.S.) were reimbursed by the AAN for expenses related to travel to subcommittee meetings where drafts of manuscripts were reviewed.

Disclosure

A.M. Pack serves on the editorial board for the journal *Epilepsy Currents*, receives royalties from UpToDate, receives funding from the NIH for serving as coinvestigator and site PI for the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study, and receives funding from Bayer for serving as a co-investigator on a study on women with epilepsy initiating a progestin IUD. An immediate family member of A.M. Pack has received personal compensation for serving as an employee of

REGENEXBIO. M. Oskoui has received personal compensation in the range of \$500–\$4,999 for serving as an officer or member of the Board of Directors for the Association des Neurologues du Quebec. The institution of M. Oskoui has received research support from Biogen, Roche Genetech, Muscular Dystrophy Canada, and the Canadian Institutes of Health Research. M. Oskoui has received personal compensation in the range of \$50,000–\$99,999 for serving as an evidence-based medicine methodologist with the AAN. M. Oskoui has a non-compensated relationship as a Member of the Medical and Scientific Advisory Committee with Muscular Dystrophy Canada. S. Williams Roberson receives research funding from the National Institute on Aging for a study related to ICU delirium and associated cognitive decline, serves on the editorial board for *Neurology Today*, and has a non-compensated relationship as a Physician Advisory Board Member with Epilepsy Foundation of Middle and Western Tennessee. D.K. Donley’s immediate family member has received compensation in the range of \$10,000–\$49,999 for serving as the vice president of Novello Physicians Organization. J. French’s institution has received research support from the Epilepsy Study Consortium, the Epilepsy Foundation (funded by UCB), GW Pharmaceuticals, the One8 Foundation, FACES (Finding a Cure for Epilepsy and Seizures), the National Institute of Neurological Disorders and Stroke (NINDS), Xenon, and Cerevel. J. French has received personal compensation in the range of \$100,000–\$499,999 for serving as a Chief Medical and Innovation Officer with the Epilepsy Foundation. J. French has had a non-compensated relationship serving as a consultant or scientific advisory board member for Alterity Therapeutics Limited, Angelini, Arvelle Therapeutics, Autifony Therapeutics Limited, Baergic Bio, Beacon Biosignals, Biogen, Biohaven Pharmaceuticals, Bloom Science Inc., BridgeBio Pharma Inc., Bright minds Biosciences, Camp4 Therapeutics Corporation, Cerebral Therapeutics, Cerecin Inc., Cerevel, Coda Biotherapeutics, Cognizance Biomarkers, Crossject, Eisai, Eliem Therapeutics, Encoded Therapeutics, Engrail, Epalex, Epihunter, Epitel Inc., Equilibre BioPharmaceuticals, Genentech Inc., Grin Therapeutics, GW Pharmaceuticals, iQure Pharma, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Knopp Biosciences, Korro Bio Inc., Leal Therapeutics, Lipocine, LivaNova, Longboard Pharmaceuticals, Lundbeck, Marinus, Mend Neuroscience, Modulight Bio, Neumirna Therapeutics, Neurelis, Neurocrine, Neuroelectrics USA Corporation, NeuroPro Therapeutics, Ono Pharmaceutical Co, Otsuka Pharmaceutical Development, Ovid Therapeutics Inc., Paladin Labs Inc., Pfizer, Praxis, PureTech LTY Inc., Rafa Laboratories Ltd., Rapport Therapeutics, Receptor, Sage Therapeutics, SK Life Science, Stoke, Supernus, Takeda, Third Rock Ventures, UCB Inc., Ventus Therapeutics, Vida Ventures Management, Xenon, and Zogenix. J. French is on the editorial board of *Lancet Neurology* and *Neurology Today*. J. French has received travel and/or meal reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study

Consortium, the Epilepsy Foundation, Angelini Pharma, Biohaven Pharmaceuticals, Cerebral Therapeutics, Neurelis, Neurocrine, Praxis, Rapport, SK Life Science, Stoke, Takeda, and Xenon. E.E. Gerard has received personal compensation in the range of \$500–\$4,999 for serving as a consultant for Greenwich Pharmaceuticals. The institution of E.E. Gerard has received research support from NIH/NINDS, Xenon Pharmaceuticals, and Eisai, Inc. (via Stanford University). E.E. Gerard has received travel reimbursements from the American Clinical Neurophysiology Society (ACNS), various institutions for CME lectures, and from the One 8 Foundation. E.E. Gerard's institution has received compensation from the One 8 Foundation for research coordinator time. The institution of an immediate family member of E.E. Gerard has received research support from NIH and Novo Nordisk. D. Gloss has received personal compensation in the range of \$500–\$4,999 for serving as a Drug Utilization Review Board Member with the West Virginia Department of Health and Human Resources. W.R. Miller has received research support from Indiana University School of Nursing as part of the Ethel Clarke Fellowship for serving as a PI for Patient Preferences for Delivery of a Web-Based Epilepsy Self-Management Intervention, has received research support from Indiana University Networks Institute for serving as a co-PI (no effort) for the study Sudden Unexpected Death in Epilepsy: Identifying Risk Factors with Social Media Mining, and receives research support from the NIH/NINDS for serving as a core investigator (P30 investigator) for the development of a brain safety lab. H.M. Munger Clary's institution has received research support from the NIH, the U.S. Department of Defense, Duke Endowment, the Susanne Marcus Collins Foundation, and Eysz, Inc. H.M. Munger Clary has received personal compensation in the range of \$500–\$4,999 for serving as a speaker with the American Epilepsy Society (AES). H.M. Munger Clary has received personal compensation in the range of \$500–\$4,999 for serving as a speaker with J. Kiffin Penry Epilepsy Education Programs. H.M. Munger Clary has received personal compensation in the range of \$500–\$4,999 for serving as a topic editor for DynaMed. H.M. Munger Clary has had non-compensated relationships as Chair of the Psychosocial Comorbidities Committee with the American Epilepsy Society, as Co-Chair of the Integrated Mental Health Care Pathways Task Force with the International League Against Epilepsy, and as Co-Chair Elect of the Resident and Fellow Education Committee with the American Clinical Neurophysiology Society. S.S. Osmundson's institution has received research support from NIH. B. McFadden serves as Executive Director for My Epilepsy Story and is uncompensated for this role, serves as an uncompensated member of the ELC Group, serves as an uncompensated patient advisor, serves as an uncompensated Patient-Centered Outcomes Research Institute (PCORI) Ambassador, and receives travel reimbursement from PCORI for attending meetings. K. Parratt has received personal compensation in the range of \$500–\$4,999 for serving on a speakers bureau for Eisai and for UCB. K.

Parratt receives funding from Zynerba for serving as a sub-investigator for the study Cannabidiol ZYNN2-CL-04 and ZYNN2-CL-04 for artrial onset seizures, receives funding from SK Life Science for serving as a subinvestigator for the study Cenobamate YKP3089C021 for partial onset seizures, has received funding from Eisai Inc. for the study Perampnel E2007-G00-335 for partial onset seizures, has received funding from Marinus Pharmaceuticals for the study Ganaxolone 10420603 for partial onset seizures, and has received honoraria from Esai for a dinner meeting lecture. P.B. Pennell's institution has received research support from the NINDS and the Eunice Kennedy Shriver National Institute of Child Health and Human Development for observational studies of people with epilepsy of childbearing potential and their children. The institution of an immediate family member of P.B. Pennell has received research support from the U.S. Department of Defense, the Environmental Protection Agency, the NIH, and Advanced Energy Consortium. P.B. Pennell has received publishing royalties from UpToDate, a publication relating to health care. P.B. Pennell has received honoraria and/or travel reimbursements from the AES, the AAN, and various academic medical institutions for CME lectures. She has received honoraria for grant reviews from the NIH and Harvard Catalyst. She has received honoraria for serving on the scientific advisory board for BRAINS, an NIH-funded study. G. Saade has received personal compensation in the range of \$500–\$4,999 for serving as a Consultant for GestVision. G. Saade has received personal compensation in the range of \$500–\$4,999 for serving on a scientific advisory or data safety monitoring board for CooperSurgical. G. Saade has served on scientific advisory boards for Sage Therapeutics and GestVision. G. Saade has received personal compensation in the range of \$5,000–\$9,999 for serving as an editor, associate editor, or editorial advisory board member for Thieme Publishing. The institution of G. Saade has received research support from Sera Prognostics, and from NICHD for clinical obstetrics issues. G. Saade has received research support from the NIH for studies related to chronic hypertension and pregnancy, human placenta evaluation, and pregnancy and cardiovascular health. G. Saade has received honoraria for speaking engagements at multiple universities and has given expert testimony, prepared an affidavit, and acted as a witness for legal proceedings regarding preeclampsia. D. Smith has received personal compensation in the range of \$10,000–\$49,999 for serving as an evidence-based medicine methodologist for the AAN. K. Sullivan has received intellectual property interests from a discovery or technology relating to health care. S.V. Thomas is deceased; to the best of our knowledge, the relevant disclosures are as follows: S.V. Thomas served as a PI of a pregnancy registry in India that has generated clinical data pertaining to the use of anti-epileptic drugs during pregnancy, received honoraria for BMJ Masterclasses on epilepsy, and received research grants from the Indian government. S.V. Thomas received personal compensation in the range of \$0–\$499 for serving as an editor, associate editor, or editorial advisory board member for Wiley

India, and served on the editorial board of the journal *Epilepsy Research*. T. Tomson's institution has received personal compensation in the range of \$500–\$4,999 for serving on a scientific advisory or data safety monitoring board for Angelini and GW Pharmaceuticals. The institution of T. Tomson has received research support from Eisai, GSK, UCB, Bial, Sanofi, Angelini, GW Pharmaceuticals, Teva Pharma, Zentiva, Accord, Ecu Pharm, SF Group, and Glenmark (for serving as a PI in the EURAP study and the International Antiepileptic Drugs and Pregnancy Registry). T. Tomson has received personal compensation in the range of \$500–\$4,999 for serving as a speaker with Angelini, Sanofi, Eisai, Sun Pharma, and UCB. T. Tomson has received funding from GSK for serving as a PI for a study on sudden unexpected death in epilepsy; has received research funding from Stockholm County Council; and has received research funding from the European Union and Nordforsk. M. Dolan O'Brien was an employee of the AAN. K. Botchway-Doe is an employee of the AAN. H. Silsbee is an employee of the AAN. M.R. Keezer's institution has received research support from UCB and Eisai. M.R. Keezer serves on the editorial board for the journals *Epilepsia* and *Neurology: Clinical Practice*. M.R. Keezer has received a salary award from the Fonds de Recherche du Québec Santé and research grants from the Centre Hospitalier de l'Université de Montréal Research Centre, the Savoy Foundation, the Canadian Frailty Network, the Fonds de Recherche du Québec Santé, TD Bank, and the Canadian Institutes of Health Research. Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures.

Publication History

Received by *Neurology* October 17, 2023. Accepted in final form February 21, 2024. Submitted and externally peer reviewed. The handling editor was Editor-in-Chief José Merino, MD, MPhil, FAAN.

Appendix Authors

Name	Location	Contribution
Alison M. Pack, MD, MPH	Department of Neurology, Columbia University, New York City	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data
Maryam Oskoui, MD, MSc	Departments of Pediatrics and Neurology & Neurosurgery, McGill University, Montreal, Quebec, Canada	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data
Shawniqua Williams Roberson, MEng, MD	Department of Neurology, Vanderbilt University Medical Center, Nashville, TN	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data

Appendix (continued)

Name	Location	Contribution
Diane K. Donley, MD	Northern Michigan Neurology and Munson Medical Center, Traverse City, MI	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design
Jacqueline French, MD	Department of Neurology, NYU Grossman School of Medicine, New York City	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data
Elizabeth E. Gerard, MD	Feinberg School of Medicine, Northwestern University, Chicago, IL	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data
David Gloss, MD, MPH&TM	The NeuroMedical Center, Baton Rouge, LA	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data
Wendy R. Miller, PhD, RN, CCRN	Epilepsy Foundation, Bowie, MD	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design
Heidi M. Munger Clary, MD, MPH	Department of Neurology, Wake Forest University School of Medicine, Winston-Salem, NC	Drafting/revision of the manuscript for content, including medical writing for content; analysis or interpretation of data
Sarah S. Osmundson, MD, MS	Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data
Brandy McFadden	My Epilepsy Story, Nashville, TN	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data
Kaitlyn Parratt, MBBS (Hons 1)	Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, Australia	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data
Page B. Pennell, MD	Department of Neurology, University of Pittsburgh School of Medicine, PA	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data
George Saade, MD	Department of Ob-Gyn, Eastern Virginia Medical School, Norfolk	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data

Continued

Appendix (continued)

Name	Location	Contribution
Don B. Smith, MD	Department of Neurology, University of Colorado School of Medicine, Aurora	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data
Kelly Sullivan, PhD	Department of Biostatistics, Epidemiology, and Environmental Health Sciences, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data
Sanjeev V. Thomas, MD, DM	Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data
Torbjörn Tomson, MD	Department of Clinical Neuroscience, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data
Mary Dolan O'Brien, MLIS, PMP	American Academy of Neurology, Minneapolis, MN	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design
Kylie Botchway-Doe	American Academy of Neurology, Minneapolis, MN	Drafting/revision of the manuscript for content, including medical writing for content
Heather M. Silsbee, MWC	American Academy of Neurology, Minneapolis, MN	Drafting/revision of the manuscript for content, including medical writing for content
Mark R. Keezer, MDCM, PhD	Centre Hospitalier de l'Université de Montréal Research Centre (CRCHUM), Quebec, Canada	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data

References

- US Census Bureau. *National Population by Characteristics: 2020-2022* [online]. Accessed January 3, 2022. [census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html](https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html).
- Stephen LJ, Harden C, Tomson T, Brodie MJ. Management of epilepsy in women. *Lancet Neurol*. 2019;18(5):481-491. doi:10.1016/S1474-4422(18)30495-2
- Harden C, Pennell P, Koppel B, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. *Neurology*. 2009;73(2):133-141. doi:10.1212/WNL.0b013e3181a6b312
- Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: management issues for women with epilepsy: focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the

- American Academy of Neurology and American Epilepsy Society. *Neurology*. 2009;73(2):142-149. doi:10.1212/WNL.0b013e3181a6b325
- Gronseth GS, Cox J, Gloss D, et al. *Clinical Practice Guideline Process Manual*, 2nd ed. American Academy of Neurology; 2017.
- Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. *Lancet Neurol*. 2018;17(6):530-538. doi:10.1016/S1474-4422(18)30107-8
- Meador K, Baker G, Finnell R, et al. In utero antiepileptic drug exposure: fetal death and malformations. *Neurology*. 2006;67(3):407-412. doi:10.1212/01.wnl.0000227919.81208.b2
- Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. *Neurology*. 2005;64(11):1874-1878. doi:10.1212/01.WNL.0000163771.96962.1F
- Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. *N Engl J Med*. 2001;344(15):1132-1138. doi:10.1056/NEJM200104123441504
- Samren EB, van Duijn CM, Lieve Christiaens GCM, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. *Ann Neurol*. 1999;46(5):739-746. doi:10.1002/1531-8249(199911)46:5<739::aid-ana9>3.0.co;2-2
- Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. *Neurology*. 2012;78(21):1692-1699. doi:10.1212/WNL.0b013e3182574f39
- Ban L, Fleming KM, Doyle P, et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. *PLoS One*. 2015;10(7):e0131130. doi:10.1371/journal.pone.0131130
- Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. *J Neurol Neurosurg Psychiatry*. 2014;85(9):1029-1034. doi:10.1136/jnnp-2013-306318
- Olafsson E, Hallgrímsson JT, Hauser WA, Ludvigsson P, Gudmundsson G. Pregnancies of women with epilepsy: a population-based study in Iceland. *Epilepsia*. 1998;39(8):887-892. doi:10.1111/j.1528-1157.1998.tb01186.x
- Vajda FJE, Graham JE, Hitchcock AA, Lander CM, O'Brien TJ, Eadie MJ. Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. *Seizure*. 2019;65:6-11. doi:10.1016/j.seizure.2018.12.006
- Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. *JAMA*. 1994;271(10):767-770. doi:10.1001/jama.1994.03510340057034
- Kaaja E, Kaaja R, Hilesmaa V. Major malformations in offspring of women with epilepsy. *Neurology*. 2003;60(4):575-579. doi:10.1212/01.wnl.0000044157.28073.dc
- Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. *J Neurol*. 2014;261(3):579-588. doi:10.1007/s00415-013-7239-x
- Mawer G, Briggs M, Baker G, et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. *Seizure*. 2010;19(2):112-119. doi:10.1016/j.seizure.2009.11.008
- Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. *Epilepsia*. 1997;38(9):981-990. doi:10.1111/j.1528-1157.1997.tb01480.x
- Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. *Epilepsia*. 1999;40(9):1231-1236. doi:10.1111/j.1528-1157.1999.tb00851.x
- Wide K, Winblad B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nationwide, population-based register study. *Acta Paediatr*. 2004;93(2):174-176. doi:10.1080/08035250310021118
- Charlton RA, Weil JG, Cunnington MC, Ray S, de Vries CS. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. *Drug Saf*. 2011;34(2):157-171. doi:10.2165/11584970-000000000-00000
- Thomas SV, Jeemon P, Pillai R, et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP). *Seizure*. 2021;93:127-132. doi:10.1016/j.seizure.2021.10.015
- Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. *Arch Neurol*. 2011;68(10):1275-1281. doi:10.1001/archneurol.2011.133
- Vajda FJ, Hitchcock A, Graham J, et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. *Eur J Neurol*. 2006;13(6):645-654. doi:10.1111/j.1468-1331.2006.01359.x
- Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. *JAMA*. 2011;305(19):1996-2002. doi:10.1001/jama.2011.624
- Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. *J Neurol Neurosurg Psychiatry*. 2006;77(2):193-198. doi:10.1136/jnnp.2005.074203
- Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P. Final results from 18 years of the International Lamotrigine Pregnancy Registry. *Neurology*. 2011;76(21):1817-1823. doi:10.1212/WNL.0b013e31821ccd18
- Meador KJ, Pennell PB, May RC, et al. Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. *Neurology*. 2020;94(14):e1502-e1511. doi:10.1212/WNL.0000000000008687

31. Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. *Neurology*. 2013;80(4):400-405. doi:10.1212/WNL.0b013e31827f0874
32. Vajda F, O'Brien T, Graham J, Hitchcock A, Lander C, Eadie M. Anti-epileptic drug exposure and risk of foetal death in utero. *Acta Neurol Scand*. 2018;137(1):20-23. doi:10.1111/ane.12816
33. Scheuerle AE, Holmes LB, Albano JD, et al. Levetiracetam Pregnancy Registry: final results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformations. *Birth Defects Res*. 2019;111(13):872-887. doi:10.1002/bdr2.1526
34. Lv H, Zhao X, Yu J. Analysis of the clinical effects of sodium valproate and levetiracetam in the treatment of women with epilepsy during pregnancy. *Evid Based Complement Alternat Med*. 2021;2021:5962200. doi:10.1155/2021/5962200
35. Sharma SR, Sharma N, Hussain M, Mobing H, Hynniewta Y. Levetiracetam use during pregnancy in women with active epilepsy: a hospital-based, retrospective study from a tertiary care hospital in North Eastern India. *Neurol India*. 2021;69(3):692-697. doi:10.4103/0028-3886.319234
36. Tripathi NK. A retrospective research to assess the usage of levetiracetam during pregnancy in epileptic mothers. *Int J Toxicol Pharmacol Res*. 2021;11:79-88.
37. Putignano D, Clavenna A, Campi R, et al. Perinatal outcome and healthcare resource utilization in the first year of life after antiepileptic exposure during pregnancy. *Epilepsy Behav*. 2019;92:14-17. doi:10.1016/j.yebeh.2018.09.033
38. Tomson T, Battino D, Bonizzoni E, et al. Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP. *Neurology*. 2015;85(7):580-588. doi:10.1212/WNL.0000000000001840
39. Vajda FJ, Hitchcock AA, Graham J, O'Brien TJ, Lander CM, Eadie MJ. The teratogenic risk of antiepileptic drug polytherapy. *Epilepsia*. 2010;51(5):805-810. doi:10.1111/j.1528-1167.2009.02336.x
40. McCluskey G, Kinney MO, Russell A, et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. *Seizure*. 2021;91:311-315. doi:10.1016/j.seizure.2021.07.002
41. Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT, EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? *Neurology*. 2008;71(10):714-722. doi:10.1212/01.wnl.0000316194.98475.d8
42. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. *Neurology*. 2008;70(22 pt 2):2152-2158. doi:10.1212/01.wnl.0000304343.45104.d6
43. Martinez Ferri M, Pena Mayor P, Perez Lopez-Fraile I, et al. Malformations and fetal death in the Spanish antiepileptic drug and pregnancy registry: results at 6 years [in Spanish]. *Neurologia*. 2009;24(6):360-365.
44. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. *Neurology*. 2015;85(10):866-872. doi:10.1212/WNL.0000000000001772
45. Mawhinney E, Campbell J, Craig J, et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important? *Seizure*. 2012;21(3):215-218. doi:10.1016/j.seizure.2012.01.005
46. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Pregnancy, delivery, and outcome for the child in maternal epilepsy. *Epilepsia*. 2009;50(9):2130-2139. doi:10.1111/j.1528-1167.2009.02147.x
47. Hernandez-Diaz S, Huybrechts KF, Desai RJ, et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. *Neurology*. 2018;90(4):e342-e351. doi:10.1212/WNL.0000000000004857
48. Dolk H, Wang H, Loane M, et al. Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. *Neurology*. 2016;86(18):1716-1725. doi:10.1212/WNL.0000000000002540
49. Bjork MH, Zoega H, Leinonen MK, et al. Association of prenatal exposure to anti-seizure medication with risk of autism and intellectual disability. *JAMA Neurol*. 2022;79(7):672-681. doi:10.1001/jamaneurol.2022.1269
50. Nadebaum C, Anderson VA, Vajda F, Reutens DC, Barton S, Wood AG. Language skills of school-aged children prenatally exposed to antiepileptic drugs. *Neurology*. 2011;76(8):719-726. doi:10.1212/WNL.0b013e31820d62c7
51. Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. *Lancet Neurol*. 2013;12(3):244-252. doi:10.1016/S1474-4422(12)70323-X
52. Gaily E, Kantola-Sorsa E, Hillesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. *Neurology*. 2004;62(1):28-32. doi:10.1212/wnl.62.1.28
53. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. *J Neurol Neurosurg Psychiatry*. 2004;75(11):1575-1583. doi:10.1136/jnnp.2003.029132
54. Eriksson K, Viinikainen K, Monkkonen A, et al. Children exposed to valproate in utero: population based evaluation of risks and confounding factors for long-term neurocognitive development. *Epilepsy Res*. 2005;65(3):189-200. doi:10.1016/j.eplepsyres.2005.06.001
55. Baker GA, Bromley RL, Briggs M, et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. *Neurology*. 2015;84(4):382-390. doi:10.1212/WNL.0000000000001182
56. Bromley RL, Calderbank R, Cheyne CP, et al. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. *Neurology*. 2016;87(18):1943-1953. doi:10.1212/WNL.0000000000003157
57. Christensen J, Grønberg TK, Sørensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. *JAMA*. 2013;309(16):1696-1703. doi:10.1001/jama.2013.2270
58. Bromley RL, Mawer GE, Briggs M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. *J Neurol Neurosurg Psychiatry*. 2013;84(6):637-643. doi:10.1136/jnnp-2012-304270
59. Veiby G, Daltveit AK, Schjølberg S, et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. *Epilepsia*. 2013;54(8):1462-1472. doi:10.1111/epi.12226
60. Wiggs KK, Rickert ME, Suján AC, et al. Antiseizure medication use during pregnancy and risk of ASD and ADHD in children. *Neurology*. 2020;95(24):e3232-e3240. doi:10.1212/WNL.00000000000010993

Access eReferences online at [Neurology.org](https://www.neurology.org).